The evolving landscape of diabetes care is witnessing a significant shift, driven by new incretin-based therapies. Presently, semaglutide has gained considerable attention, but rival medications like tirzepatide, https://philiptduf629138.mpeblog.com/74664753/the-future-of-diabetes-comparing-tirzepatide-semaglutide-retatrutide-and-cagrilintide